-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, August 19 News On August 17, CSPC Ouyi Pharmaceutical Co.
, Ltd.
received the CDE acceptance for the listing application of troxagliptin succinate tablets submitted for imitation of category 3
.
Trixagliptin is a DPP-4 inhibitor and is the world's first oral hypoglycemic agent once a week
.
At present, 6 DPP-4 inhibitors (excluding compound prescriptions) have been approved for listing in China.
In 2020, the total sales volume in Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 3 billion yuan
.
, Ltd.
received the CDE acceptance for the listing application of troxagliptin succinate tablets submitted for imitation of category 3
.
Trixagliptin is a DPP-4 inhibitor and is the world's first oral hypoglycemic agent once a week
.
At present, 6 DPP-4 inhibitors (excluding compound prescriptions) have been approved for listing in China.
In 2020, the total sales volume in Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 3 billion yuan
.
Source: CDE official website
Troxagliptin succinate is a new long-acting oral hypoglycemic drug developed by Takeda and Furiex.
It is a dipeptidyl peptidase 4 (DPP-4) inhibitor.
It reduces the activity of dipeptidyl peptidase 4 by inhibiting the activity of DPP-4.
The decomposition of human glucagon-like peptide-1 (GLP-1) promotes insulin secretion and plays a role in lowering blood sugar
.
The product was approved for marketing in Japan in March 2015 and is the world's first oral hypoglycemic agent once a week
.
It is a dipeptidyl peptidase 4 (DPP-4) inhibitor.
It reduces the activity of dipeptidyl peptidase 4 by inhibiting the activity of DPP-4.
The decomposition of human glucagon-like peptide-1 (GLP-1) promotes insulin secretion and plays a role in lowering blood sugar
.
The product was approved for marketing in Japan in March 2015 and is the world's first oral hypoglycemic agent once a week
.
At present original research product has not yet approved the import, Cologne, CSPC Europa two companies to submit a listing application generic category 3, in which Cologne is the first, if successful patent challenge to the original research, follow-up in the domestic market will have a great first Development advantage
.
.
On August 5, 2021, the official website of the State Food and Drug Administration showed that Tanabe Mitsubishi Pharmaceutical's titagliptin hydrobromide tablets were approved for import
.
According to data from Meinenet, as of now, 6 DPP-4 inhibitors in China have been approved for marketing, all of which are daily preparations and are administered once or twice a day
.
.
According to data from Meinenet, as of now, 6 DPP-4 inhibitors in China have been approved for marketing, all of which are daily preparations and are administered once or twice a day
.
DPP-4 inhibitors listed in China
Note: Domestic sales refer to the total sales of Chinese public medical institutions and physical pharmacies in Chinese cities
Source: Mi Nei Net Database
In 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and China’s urban physical pharmacies terminal DPP-4 inhibitors (excluding compound) sales volume exceeded 3 billion yuan, year-on-year Increased by 29%
.
.
Sales of terminal DPP-4 inhibitors in physical pharmacies in cities in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
In 2020, the sales scale of terminal DPP-4 inhibitors in physical pharmacies in cities in China is close to 600 million yuan, and the growth rate has slowed down
.
With the increase in medical insurance, DPP-4 inhibitors have expanded significantly in the terminal capacity of public medical institutions in China
.
.
With the increase in medical insurance, DPP-4 inhibitors have expanded significantly in the terminal capacity of public medical institutions in China
.
Source: Mi Nei.
com database, CDE official website, etc.
com database, CDE official website, etc.
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of August 18th, if there are any omissions, please correct me!
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of August 18th, if there are any omissions, please correct me!
Medical Network, August 19 News On August 17, CSPC Ouyi Pharmaceutical Co.
, Ltd.
received the CDE acceptance for the listing application of troxagliptin succinate tablets submitted for imitation of category 3
.
Trixagliptin is a DPP-4 inhibitor and is the world's first oral hypoglycemic agent once a week
.
At present, 6 DPP-4 inhibitors (excluding compound prescriptions) have been approved for listing in China.
In 2020, the total sales volume in Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 3 billion yuan
.
, Ltd.
received the CDE acceptance for the listing application of troxagliptin succinate tablets submitted for imitation of category 3
.
Trixagliptin is a DPP-4 inhibitor and is the world's first oral hypoglycemic agent once a week
.
At present, 6 DPP-4 inhibitors (excluding compound prescriptions) have been approved for listing in China.
In 2020, the total sales volume in Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 3 billion yuan
.
Source: CDE official website
Troxagliptin succinate is a new long-acting oral hypoglycemic drug developed by Takeda and Furiex.
It is a dipeptidyl peptidase 4 (DPP-4) inhibitor.
It reduces the activity of dipeptidyl peptidase 4 by inhibiting the activity of DPP-4.
The decomposition of human glucagon-like peptide-1 (GLP-1) promotes insulin secretion and plays a role in lowering blood sugar
.
The product was approved for marketing in Japan in March 2015 and is the world's first oral hypoglycemic agent once a week
.
It is a dipeptidyl peptidase 4 (DPP-4) inhibitor.
It reduces the activity of dipeptidyl peptidase 4 by inhibiting the activity of DPP-4.
The decomposition of human glucagon-like peptide-1 (GLP-1) promotes insulin secretion and plays a role in lowering blood sugar
.
The product was approved for marketing in Japan in March 2015 and is the world's first oral hypoglycemic agent once a week
.
At present original research product has not yet approved the import, Cologne, CSPC Europa two companies to submit a listing application generic category 3, in which Cologne is the first, if successful patent challenge to the original research, follow-up in the domestic market will have a great first Development advantage
.
.
On August 5, 2021, the official website of the State Food and Drug Administration showed that Tanabe Mitsubishi Pharmaceutical's titagliptin hydrobromide tablets were approved for import
.
According to data from Meinenet, as of now, 6 DPP-4 inhibitors in China have been approved for marketing, all of which are daily preparations and are administered once or twice a day
.
.
According to data from Meinenet, as of now, 6 DPP-4 inhibitors in China have been approved for marketing, all of which are daily preparations and are administered once or twice a day
.
DPP-4 inhibitors listed in China
Note: Domestic sales refer to the total sales of Chinese public medical institutions and physical pharmacies in Chinese cities
Source: Mi Nei Net Database
In 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and China’s urban physical pharmacies terminal DPP-4 inhibitors (excluding compound) sales volume exceeded 3 billion yuan, year-on-year Increased by 29%
.
.
Sales of terminal DPP-4 inhibitors in physical pharmacies in cities in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
In 2020, the sales scale of terminal DPP-4 inhibitors in physical pharmacies in cities in China is close to 600 million yuan, and the growth rate has slowed down
.
With the increase in medical insurance, DPP-4 inhibitors have expanded significantly in the terminal capacity of public medical institutions in China
.
.
With the increase in medical insurance, DPP-4 inhibitors have expanded significantly in the terminal capacity of public medical institutions in China
.
Source: Mi Nei.
com database, CDE official website, etc.
com database, CDE official website, etc.
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of August 18th, if there are any omissions, please correct me!
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of August 18th, if there are any omissions, please correct me!
Medical Network, August 19 News On August 17, CSPC Ouyi Pharmaceutical Co.
, Ltd.
received the CDE acceptance for the listing application of troxagliptin succinate tablets submitted for imitation of category 3
.
Trixagliptin is a DPP-4 inhibitor and is the world's first oral hypoglycemic agent once a week
.
At present, 6 DPP-4 inhibitors (excluding compound prescriptions) have been approved for listing in China.
In 2020, the total sales volume in Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 3 billion yuan
.
, Ltd.
received the CDE acceptance for the listing application of troxagliptin succinate tablets submitted for imitation of category 3
.
Trixagliptin is a DPP-4 inhibitor and is the world's first oral hypoglycemic agent once a week
.
At present, 6 DPP-4 inhibitors (excluding compound prescriptions) have been approved for listing in China.
In 2020, the total sales volume in Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 3 billion yuan
.
Source: CDE official website
Troxagliptin succinate is a new long-acting oral hypoglycemic drug developed by Takeda and Furiex.
It is a dipeptidyl peptidase 4 (DPP-4) inhibitor.
It reduces the activity of dipeptidyl peptidase 4 by inhibiting the activity of DPP-4.
The decomposition of human glucagon-like peptide-1 (GLP-1) promotes insulin secretion and plays a role in lowering blood sugar
.
The product was approved for marketing in Japan in March 2015 and is the world's first oral hypoglycemic agent once a week
.
It is a dipeptidyl peptidase 4 (DPP-4) inhibitor.
It reduces the activity of dipeptidyl peptidase 4 by inhibiting the activity of DPP-4.
The decomposition of human glucagon-like peptide-1 (GLP-1) promotes insulin secretion and plays a role in lowering blood sugar
.
The product was approved for marketing in Japan in March 2015 and is the world's first oral hypoglycemic agent once a week
.
At present original research product has not yet approved the import, Cologne, CSPC Europa two companies to submit a listing application generic category 3, in which Cologne is the first, if successful patent challenge to the original research, follow-up in the domestic market will have a great first Development advantage
.
Enterprise business enterprise.
On August 5, 2021, the official website of the State Food and Drug Administration showed that Tanabe Mitsubishi Pharmaceutical's titagliptin hydrobromide tablets were approved for import
.
According to data from Meinenet, as of now, 6 DPP-4 inhibitors in China have been approved for marketing, all of which are daily preparations and are administered once or twice a day
.
.
According to data from Meinenet, as of now, 6 DPP-4 inhibitors in China have been approved for marketing, all of which are daily preparations and are administered once or twice a day
.
DPP-4 inhibitors listed in China
Note: Domestic sales refer to the total sales of Chinese public medical institutions and physical pharmacies in Chinese cities
Source: Mi Nei Net Database
In 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and China’s urban physical pharmacies terminal DPP-4 inhibitors (excluding compound) sales volume exceeded 3 billion yuan, year-on-year Increased by 29%
.
Hospital hospital hospital pharmacy pharmacy pharmacy.
Sales of terminal DPP-4 inhibitors in physical pharmacies in cities in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
In 2020, the sales scale of terminal DPP-4 inhibitors in physical pharmacies in cities in China is close to 600 million yuan, and the growth rate has slowed down
.
With the increase in medical insurance, DPP-4 inhibitors have expanded significantly in the terminal capacity of public medical institutions in China
.
.
With the increase in medical insurance, DPP-4 inhibitors have expanded significantly in the terminal capacity of public medical institutions in China
.
Source: Mi Nei.
com database, CDE official website, etc.
com database, CDE official website, etc.
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of August 18th, if there are any omissions, please correct me!
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of August 18th, if there are any omissions, please correct me!
